Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.

Antimicrobial Agents and Chemotherapy
Seng Gee LimFranck Rousseau

Abstract

Emtricitabine (FTC) is approved for the treatment of human immunodeficiency virus. FTC and clevudine (CLV) have activity against hepatitis B virus (HBV). This report summarizes the results of a double-blind, multicenter study of patients with chronic hepatitis B who had completed a phase 3 study of FTC and were randomized 1:1 to 200 mg FTC once daily (QD) plus 10 mg CLV QD or 200 mg FTC QD plus placebo for 24 weeks with 24 weeks of follow-up. One hundred sixty-three patients were treated (82 with FTC plus CLV [FTC+CLV] and 81 with FTC); 72% were men, 53% were Asian, 47% were Caucasian, and 52% were hepatitis B e antigen positive, and the median baseline HBV DNA level was 6 log(10) copies/ml. After 24 weeks of treatment, 74% (FTC+CLV) versus 65% (FTC alone) had serum HBV DNA levels of <4,700 copies/ml (P = 0.114) (Digene HBV Hybrid Capture II assay). Twenty-four weeks posttreatment, the mean change in serum HBV DNA levels from baseline was -1.25 log(10) copies/ml (FTC+CLV), 40% had undetectable viremia (versus 23% for FTC alone), and 63% had normal alanine aminotransferase levels (versus 42% for FTC alone) (P < or = 0.025 for all endpoints). The safety profile was similar between arms during treatment, with less posttreatment ex...Continue Reading

References

Jul 9, 1998·The New England Journal of Medicine·C L LaiD F Gray
Oct 21, 1999·The New England Journal of Medicine·J L DienstagN A Brown
May 29, 2001·Gastroenterology·A S LokJ H Hoofnagle
Aug 29, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Béatrice SeignèresFabien Zoulim
Feb 28, 2003·The New England Journal of Medicine·Stephanos J HadziyannisUNKNOWN Adefovir Dipivoxil 438 Study Group
Feb 28, 2003·The New England Journal of Medicine·Patrick MarcellinUNKNOWN Adefovir Dipivoxil 437 Study Group
Jan 8, 2004·Journal of Hepatology·Antonio CraxìCalogero Cammà
Mar 16, 2004·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Emmet B KeeffeTeresa L Wright
Jul 9, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Patrick MarcellinHyo-Suk Lee
Sep 17, 2004·The New England Journal of Medicine·Patrick MarcellinUNKNOWN Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group

❮ Previous
Next ❯

Citations

Jan 27, 2009·Current Gastroenterology Reports·John D Scott, Brian McMahon
Jun 10, 2011·Current Hepatitis Reports·Navin Paul, Steven-Huy Han
Sep 9, 2008·Gastroentérologie Clinique Et Biologique·T AsselahP Marcellin
Jan 16, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Emmet B Keeffe, Patrick Marcellin
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Norah A Terrault
Apr 1, 2008·Alimentary Pharmacology & Therapeutics·M Kumar, S K Sarin
Oct 9, 2007·Liver International : Official Journal of the International Association for the Study of the Liver·Dan RudinVincent M Sottile
Nov 22, 2011·Liver International : Official Journal of the International Association for the Study of the Liver·Olivier LadaPatrick Marcellin
Dec 17, 2005·Journal of Hepatology·Antonio CraxìCalogero Cammà
Aug 12, 2009·Journal of Hepatology·Russell D Fleischer, Anna S F Lok
Oct 3, 2007·Antiviral Chemistry & Chemotherapy·Mark A FeitelsonRaymond F Schinazi
Jul 7, 2007·Archives of Medical Research·Margarita PardoVicente Carreño
Nov 1, 2006·Expert Review of Clinical Immunology·Rosa ZampinoGiuseppe Ruggiero
Jul 1, 2010·The Annals of Pharmacotherapy·Lauren M HynickaPunam H Patel
Jun 1, 2010·Viruses·Erik De ClercqJohan Neyts
Feb 3, 2007·The American Journal of Gastroenterology·Man-Fung Yuen, Ching-Lung Lai
Aug 21, 2013·Antimicrobial Agents and Chemotherapy·Guoyi WuMark A Feitelson
Oct 20, 2006·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Robert G Gish, Timothy McCashland
Jan 2, 2007·Current Opinion in Infectious Diseases·Gail Matthews
Oct 30, 2007·Reviews in Medical Virology·Geoffrey FérirErik De Clercq
Oct 3, 2006·Expert Review of Anti-infective Therapy·Brent E KorbaMichael J Otto
Dec 17, 2008·Expert Review of Gastroenterology & Hepatology·Manoj Kumar, Shiv K Sarin
Oct 31, 2009·World Journal of Hepatology·Konstantinos Tziomalos
May 24, 2011·European Journal of Gastroenterology & Hepatology·Hatef MassoumiHui-Hui Tan
Nov 30, 2006·World Journal of Gastroenterology : WJG·Zahariy-A Krastev

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Patrick MarcellinHyo-Suk Lee
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Byung Chul YooHyo-Suk Lee
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Byung Chul YooHyo-Suk Lee
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Hyo-Suk LeeByung Chul Yoo
JAMA : the Journal of the American Medical Association
Chien-Jen ChenREVEAL-HBV Study Group
© 2022 Meta ULC. All rights reserved